Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 290

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 290
---
 monthly rental obligations under non-cancellable leases are approximately 
 $5.5 (including $3 for administrative expenses).                                                                                        |

As part of the agreement, the Company
has provided the landlord with a bank guarantee of approximately of $7 (NIS 27 thousand) which is valid until February 2025.

Future minimum lease payments under non-cancelable
operating leases as of December 31, 2023 are as follows:

| 2024 |     | USD | 66 |
|:-----|:----|:----|---:|
|      |     | $   | 66 |

The Company elected to apply the practical
expedients permitted under the transition guidance in ASU 2016-02, and the Company also elected not to apply the recognition requirements
in ASU 2016-02 to short-term leases (less than 12 months) as of the adoption date. As such, there was no impact on the Company’s
financial statements as a result of adopting ASU 2016-02.

| 6. | In 2019, a controversy                                                                                                                  
 has arisen between the Company and CSL Behring GmbH, or CSL, whether certain unshipped minimum purchase commitments for fibrinogen      
 from 2018 to 2020 are to be paid by the Company pursuant to a Framework Supply Agreement dated March 8, 2016, or Framework Supply       
 Agreement, by and between the Company and CSL, whereby CSL agreed to supply the Company with fibrinogen. On January 14, 2020, the       
 Company received a termination letter, or CSL Termination Letter. In the CSL Termination Letter, CSL demanded a total amount of $820,   
 claiming it was owed the minimum purchase commitment amounts under the Framework Supply Agreement not paid by the Company in 2018       
 and 2019. In a subsequent correspondence, CSL additionally demanded interest and damages for lost profit, with an aggregate demand      
 amount of $1,476. The Company has disputed CSL’s payment demand and contends that CSL’s demands are baseless under the                  
 Framework Supply Agreement, as the minimum purchase commitment under the Framework Supply Agreement is conditional upon first obtaining 
 approval of the FDA and the European Medicines Evaluation Agency, or EMEA, and other quality and clinical milestones, none of which     
 has occurred. Notwithstanding, CSL claimed to have obtained a valid German court order in its favor and to endeavor to seek for its     
 enforcement in Israel. Company’s position is that CSL’s